Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin versus docetaxel + fluorouracil + cisplatin induction chemotherapy for unresectable locally advanced head and neck cancer
PACTR202406479424515Phase 3Recruiting
- Sponsor
- Suez Canal University
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of gemcitabine, cisplatin, docetaxel and fluorouracil in head and neck cancer (HNC) (2 arms), sponsored by Suez Canal University. Primary endpoint: Primary efficacy comparison. Started Jan 2023; status: recruiting.
02
Drugs
gemcitabinecisplatindocetaxelfluorouracil
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on PACTR202406479424515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202406479424515.